Patients treated with intravitreal triamcinolone acetonide [from Gallenga and Lobefalo] and Response to correspondence [from Kocabora]  ||FREE PAPER||
Pier E Gallenga1, Lucio Lobefalo21University Eye Clinic, G.D’Annunzio University, Chieti, Italy; 2Ethical Committee, Italian Ophthalmological Society – SOI, ItalyThe paper by Kocabora and coworkers (2008) underlines the message that patients treated with intravitreal tria...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/cd005902712d4e0daab2add1786f68cf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Pier E Gallenga1, Lucio Lobefalo21University Eye Clinic, G.D’Annunzio University, Chieti, Italy; 2Ethical Committee, Italian Ophthalmological Society – SOI, ItalyThe paper by Kocabora and coworkers (2008) underlines the message that patients treated with intravitreal triamcinolone acetonide are at risk of increased intraocular pressure (IOP) even after the clearance period of the drug. Furthermore, the development of intractable secondary glaucoma requiring surgical intervention is clear advice to monitor these patients carefully. M Selim KocaboraVatan caddesi, Vakif Gureba Egitim ve Arastirma Hastanesi, Fatih, 34 000, Istanbul, Turkey.We thank Dr. Gallenga and Dr. Lobefalo for their interest in our article (Kocabora et al 2008) and for their comments. We agree with them on the importance of pharmacovigilance and of warning the ophthalmology community about the potential risks of intravitreal triamcinolone (IVTA). We should always follow the principle of primum, non nocere in our medical practices. ... |
|---|